SAN DIEGO, March 23, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, today
announced the appointment of James S.
Mazzola as vice president, Corporate Communications and
Investor Relations, reporting to President and CEO Dr. Helen Torley.
Mr. Mazzola will be responsible for the creation and
implementation of integrated communication and branding efforts
that support Halozyme's business objectives to all key
stakeholders, including investors, employees, media, corporate
partners, patients, clinicians and the scientific community.
"As we grow our business, Jim will play a key role helping to
shape our brand, support our investor outreach and align our
marketing communication efforts across all stakeholders," said Dr.
Torley. "His background makes him a strong complement to the very
senior management team we have been building to drive results in
our product programs, make a difference in the lives of patients
and continue to create value for shareholders."
Mr. Mazzola brings nearly 25 years of public relations,
financial communication and marketing communication experience to
Halozyme. He was previously senior vice president of Global
Marketing, Communication and Investor Relations for CareFusion,
responsible for the company's integrated marketing, communication
and brand strategy, investor relations, sales operations and
serving as president of the CareFusion Foundation. Prior to joining
CareFusion, he was senior vice president of Global Communication at
Cardinal Health where he led corporate public relations, financial
communication and the Cardinal Health Foundation. At Dell, he held
roles of increasing responsibility, including managing all product
communication and supporting communication programs for Chairman
and CEO Michael Dell. He began his
career at NCR Corp., and earned his BA in Communication and MBA
from the University of Dayton.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, our investigational drug
PEGPH20, applies a unique approach to targeting solid tumors,
allowing increased access of co-administered cancer drug therapies
to the tumor. PEGPH20 is currently in development for
metastatic pancreatic cancer and non-small cell lung cancer and has
potential across additional cancers in combination with different
types of cancer therapies. In addition to its proprietary product
portfolio, Halozyme has established value-driving partnerships with
leading pharmaceutical companies including Roche, Pfizer, Janssen
and Baxter for its drug delivery
platform, ENHANZE™, which enables biologics and small molecule
compounds that are currently administered intravenously to be
delivered subcutaneously. Halozyme is headquartered in San Diego, CA. For more information on how we
are innovating, please visit our corporate website at
www.halozyme.com.
Safe Harbor Statement
In addition to historical
information, the statements set forth above include forward-looking
statements that involve risk and uncertainties that could cause
actual results to differ materially from those in the
forward-looking statements. The forward-looking statements are also
identified through use of the words "believe," "enable," "may,"
"will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in
forward-looking statements as a result of several factors,
including unexpected results or delays in development and
regulatory review, regulatory approval requirements, unexpected
adverse events, competitive conditions and the continuation of the
Halozyme-Janssen and other collaborations. These and other factors
that may result in differences are discussed in greater detail in
the Company's Annual Report on Form 10-K filed with the Securities
and Exchange Commission on March 2,
2015.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-appoints-james-mazzola-to-lead-corporate-communications-investor-relations-300054117.html
SOURCE Halozyme Therapeutics, Inc.